Zhang Appointed Board Directors

Professor Li Zhang Appointed to MASCC Board of Directors

August 2015
MASCC President David Warr, MD, is pleased to announce the appointment of Professor Li Zhang, MD, of Sun Yat-Sen University Center in Guangzhou, China to MASCC’s Board of Directors. Warr, who has visited China several times and met with prominent Chinese oncologists states that none are more influential in the area of supportive care as Dr. Zhang, who is recognized as a leader in research and a mentor to junior facult

Dr. Zhang is currently Professor of Medical Oncology and Deputy Director of the Lung Cancer Research Center at Sun Yat-Sen University (SYSU). He is also Director of the National Anti-Cancer Drug Clinical Research Centre and Vice Chair of the Department of Medical Oncology at Sun Yat-Sen University Cancer Centre (SYSUCC).

Dr. Zhang received the Bachelor of Medicine and Master of Clinical Oncology degrees from Sun Yat-Sen University. He has served as a Visiting Fellow at the Institut Gustave Roussy in Paris, France, the Fox Chase Cancer Center in Philadelphia, Pennsylvania, USA, and the MD Anderson Cancer Center in Houston, Texas, USA.

Dr. Zhang’s supportive care interests focus on the treatment of cancer pain, cancer-induced anemia, nausea and vomiting, and the treatment of bone metastases with bisphosphonate. Other research interests include the development of molecular, prognostic, and therapeutic approaches to the care of patients with lung cancer, colorectal cancer, and nasopharyngeal carcinoma.

Dr. Zhang has served as principal investigator or steering committee member of several international phase III clinical trials. He is currently a member of the NCCN Clinical Practice Guidelines in Oncology™ (Chinese Version) Lung Cancer, Colon/Rectal Cancer and Head and Neck Cancer Panel. Dr. Zhang has served as Editor or Editorial Board member of numerous professional journals in the fields of clinical oncology and cancer research. He has published more than 90 clinical research papers in such peer-reviewed journals as Journal of Clinical Oncology, Lancet Oncology, Cancer, Cancer Gene Therapy, Journal of Thoracic Oncology, Lung Cancer, Cancer Chemotherapy and Pharmacology, Oncology, Clinical Lung Cancer, and Medical Oncology, and he has presented abstracts at many major congresses, including ASCO, AACR, WCLC, and ESMO. He also serves as Senior Consultant to the Centre of Drug Evaluation, Chinese Food and Drug Administration (SFDA) and drafted the SFDA Guidance for Industry: Clinical Trial for the Approval of Cancer Drugs and Biologics (Second Version, 2006).

All of us at MASCC extend a warm welcome to Dr. Zhang and sincere congratulations on his appointment to MASCC’s Board of Directors!